Autologous Dendritic Cell Vaccine in Patients With Soft Tissue Sarcoma
Last updated on July 2021Recruitment
- Recruitment Status
- Enrolling by invitation
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Neoplasms, Connective and Soft Tissue
- Sarcoma
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Vaccination is carried out on the planned days ± 3 days All examinations must be performed before the vaccine is administered. Full physical examination. Assessment of vital signs (blood pressure, temperature, heart rate), the general condition of the patient and physical activity. Evaluation of con...
Vaccination is carried out on the planned days ± 3 days All examinations must be performed before the vaccine is administered. Full physical examination. Assessment of vital signs (blood pressure, temperature, heart rate), the general condition of the patient and physical activity. Evaluation of concomitant therapy. Assessment of vital signs. Laboratory safety and immunological indicators Assessment of adverse events, symptoms and syndromes of the disease. Introduction of CV in accordance with the dose determined for a given vaccination (see section 9.2. - procedures for delivery and use) After administration, patients are observed for at least 1 hour. An assessment of vital indicators. Undesirable effects detected at the introduction are recorded.
Tracking Information
- NCT #
- NCT01883518
- Collaborators
- Not Provided
- Investigators
- Study Chair: Yuriy Komarov, PhD N. N. Petrov Research Institute of oncology
Get Well Soon